Forward BIOLABS announced today that it is partnering with BioForward Wisconsin to launch Innovation to Commercialization Pipeline (ICP), a new statewide program designed to help early-stage biohealth companies across Wisconsin navigate the journey from discovery to market.

According to a release, companies in Biomedical Research & Testing, Biopharmaceuticals, Diagnostics, Digital Health & Software, Health & Wellness Solutions, Life Sciences, Medical Devices, Reagents and Tools & Instrumentation are encouraged to apply. Accepted companies will receive tailored support designed to accelerate their commercialization journey.

“In developing the program, we consistently heard from leaders how essential it is for young companies to be prepared not only to raise seed funding but also to position themselves for larger, follow-on investment,” Forward BIOLABS CEO and Co-Founder Jessica Martin Eckerly said in a statement. “To succeed, these emerging companies need support to hit key milestones that help them secure initial investment from Wisconsin’s early-stage investors and continued support to bridge the gap in attracting additional capital from investors nationwide. The ICP program was created to help close these gaps and position Wisconsin’s biohealth companies for growth.”

The application window opens Monday, Oct. 13 and closes on Friday, Nov. 14. It can be done online.

Selected companies will be notified before the end of December.